27,391 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Granahan Investment Management LLC

Granahan Investment Management LLC acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 1st quarter, Holdings Channel.com reports. The firm acquired 27,391 shares of the company’s stock, valued at approximately $2,887,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. NEXTBio Capital Management LP purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter worth $20,055,000. Jennison Associates LLC purchased a new position in shares of Protagonist Therapeutics during the fourth quarter valued at $28,924,000. Clearbridge Investments LLC bought a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $42,783,000. Keystone Investors PTE Ltd. bought a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $2,305,000. Finally, Eagle Health Investments LP bought a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $5,005,000. 98.63% of the stock is owned by institutional investors.

Insider Transactions at Protagonist Therapeutics

In other news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the transaction, the director owned 7,825 shares of the company’s stock, valued at $922,880.50. The trade was a 53.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bryan Giraudo sold 36,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $100.14, for a total transaction of $3,605,040.00. Following the transaction, the director owned 27,825 shares of the company’s stock, valued at approximately $2,786,395.50. This trade represents a 56.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 161,130 shares of company stock valued at $16,355,220 in the last 90 days. Insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $136.11 on Friday. The stock’s 50-day moving average is $116.79 and its 200 day moving average is $101.33. Protagonist Therapeutics, Inc. has a 1-year low of $50.49 and a 1-year high of $143.29. The company has a market cap of $8.75 billion, a P/E ratio of -75.20 and a beta of 1.79.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The business had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on PTGX shares. Wolfe Research initiated coverage on shares of Protagonist Therapeutics in a report on Thursday, May 21st. They set an “outperform” rating and a $135.00 target price on the stock. Wall Street Zen upgraded shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. The Goldman Sachs Group reiterated a “neutral” rating and set a $110.00 price objective on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. Finally, TD Cowen reissued a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $123.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.